Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumors 1

Interventions

pembrolizumab 3olaparib 2atezolizumab 2Trastuzumab 2zimberelimab 1tocilizumab 1spartalizumab 1pralsetinib 1pertuzumab 1ipatasertib 1inavolisib 1fludarabine 1entrectinib 1alectinib 1Radiotherapy 1Methotrexate 1Immune Checkpoint Inhibitors 1Docetaxel 1Cyclophosphamide 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Solid Tumors × pralsetinib × Clear all
NCT04589845 2026-05-08

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Hoffmann-La Roche

Phase 2 Active not recruiting
920 enrolled 1 FDA
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡